CompletedNCT06982651
A Study on the Safety, Pharmacokinetics, and Food Effects of MI078 Capsules
Medication studyAges 18–45ChinaDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- ChangshaSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: September 9, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 98
- Sponsor
- Nanjing Minova Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- China
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT06982651
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Parallel-Controlled Phase Ⅰ Clinical Trial of the Tolerability, Safety, Pharmacokinetics and Food Effects of MI078 Capsules in Single and Multiple Doses in Healthy Chinese Subjects
Get this study by email
Recruitment & locations
CompletedChangsha
Questions about this study
Who is behind this study?
The study sponsor is Nanjing Minova Pharmaceutical Co., Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including MI078 and Placebo.
Who was this study for?
Listed age limits: 18 years to 45 years.
